Clinical Trial
doi: 10.1007/BF00142686.
Topically applied levobunolol does not cause changes in the corneal endothelium
Affiliations
- PMID: 2103529
- DOI: 10.1007/BF00142686
Item in Clipboard
Clinical Trial
Topically applied levobunolol does not cause changes in the corneal endothelium
Doc Ophthalmol.
1990.
Abstract
The corneal endothelium was examined in ten patients suffering from ocular hypertension before, during and after four months of topical levobunolol treatment. The untreated fellow eye served as a control. The number of endothelial cells, determined with a McIntyre eyepiece and an Eisner's contact lens, was not affected by levobunolol therapy. In addition, the morphology of the cell did not appear to be affected by the drug.
Similar articles
-
Efficacy and safety of once-daily levobunolol for glaucoma therapy.Can J Ophthalmol. 1989 Feb;24(1):2-6. Can J Ophthalmol. 1989. PMID: 2653592 Clinical Trial.
-
Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort.Br J Ophthalmol. 1987 Apr;71(4):250-3. doi: 10.1136/bjo.71.4.250. Br J Ophthalmol. 1987. PMID: 2883990 Free PMC article. Clinical Trial.
-
A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.Ophthalmologica. 1994;208(1):32-6. doi: 10.1159/000310446. Ophthalmologica. 1994. PMID: 8145982 Clinical Trial.
-
Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs. 1987 Dec;34(6):648-61. doi: 10.2165/00003495-198734060-00002. Drugs. 1987. PMID: 2892662 Review.
-
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.J Clin Pharmacol. 1994 Aug;34(8):795-803. doi: 10.1002/j.1552-4604.1994.tb02042.x. J Clin Pharmacol. 1994. PMID: 7962666 Review.